Dr. Yasir Rawjee
#448Managing Director and CEO
58
Age
32y
Exp
5y
Tenure
5/10
Risk
🎓 B.Sc. · St. Xavier's College, University of Bombay
📜 PhD · Texas A&M University
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
6
Agre
4
Neur
Alivus Life
Healthcare · Mid Cap
Early Growth · Innovation-Led
About
Dr. Yasir Rawjee is the Managing Director and CEO of Alivus Life, a Mid Cap company in the Healthcare sector with a market cap of ₹11K Cr. A Transformational leader with 32 years of experience, he is known for data-driven decision-making and organic builder strategy. Focuses on technical depth and R&D capabilities typical of an industry-leading pharmaceutical leadership approach.
FAQ
What is Dr. Yasir Rawjee's leadership style?
Dr. Yasir Rawjee is classified as a Transformational leader. He is data-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Dr. Yasir Rawjee's educational background?
Dr. Yasir Rawjee holds a B.Sc. from St. Xavier's College, University of Bombay and a PhD from Texas A&M University.
Who is the CEO of Alivus Life?
Dr. Yasir Rawjee is the Managing Director and CEO of Alivus Life. He has been with the company for 5 years and in the current role for 5 years.
Leadership DNA
ArchetypeTransformational
MotivationCategory Creator
CrisisRestructurer
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Focuses on technical depth and R&D capabilities typical of an industry-leading pharmaceutical leadership approach.”
⚡ Crisis●●●●○
Dr. Rawjee has focused on streamlining Glenmark Life Sciences' operations and portfolio optimization to improve margins and operational efficiency.
🎯 Motivation●●●○○
His leadership emphasizes high-value product innovation and complex API development to carve out a niche in the specialty pharmaceutical space.
👥 People●●●●○
His leadership style is explicitly defined by a data-driven, analytical approach to decision-making and operational performance management.
📈 Growth●●●●○
He has prioritized internal R&D capabilities and operational excellence to drive growth rather than relying on aggressive M&A.
💡 Innovation●●●●○
The company focuses on high-quality complex generics and specialty products that leverage existing market demand rather than inventing new therapeutic categories.
🏃 Pace●●●●○
Operates with a methodical approach to regulatory filings and long-term capacity expansion in the specialty pharmaceutical space.
🌱 Purpose●●●○○
Focuses on affordable access to specialty medicines as a core business strategy alongside standard ESG reporting requirements.
🏷️ Brand●●●●○
Reputation is built on manufacturing excellence and the ability to handle complex chemical processes rather than consumer-facing brand marketing.
🤝 Customer●●●●●
Primary business model involves supplying specialty and generic drugs to hospitals, pharmacy chains, and global healthcare distributors.
💼 Employer●●●○○
Known for deep technical exposure in manufacturing and R&D, attracting professionals seeking to build expertise in complex drug development.
📋 Mandate
Requires disciplined product pipeline development and regulatory navigation to establish market share in the highly competitive pharma sector.
🏢 Culture●●●○○
Drug manufacturing and generic focus requires a high level of R&D investment and adherence to technical excellence rather than just administrative processes.
Financials
Revenue FY25₹2K Cr
PAT FY25₹486 Cr
Rev CAGR 5Y3.9%
OPM26.7%
NPM20.8%
ROE17.2%
ROCE21.2%
P/E21.4
Fwd P/E18.7
P/B3.8
D/E2
Promoter76.1%
Institutional10.6%
Mkt Cap₹11K Cr
Compensation
To Be Published
Data being verified from audited reports
